Stay updated on 89Zr-Pembrolizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the 89Zr-Pembrolizumab in NSCLC Clinical Trial page.

Latest updates to the 89Zr-Pembrolizumab in NSCLC Clinical Trial page
- Check5 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3. This appears to be a minor site version update with no visible changes to core content or functionality.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedAdded Revision: v3.4.2 and removed the funding-lapse notice along with Revision: v3.4.1.SummaryDifference0.5%

- Check41 days agoChange DetectedAdded a site-wide government funding lapse notice indicating possible delays in updates and support availability. Updated the site revision from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check48 days agoChange DetectedThe changes are minor UI/text updates: a new 'Show glossary' option and new footer/version details ('Last Update Submitted that Met QC Criteria' and 'Revision: v3.4.0'), plus removal of older labels ('Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4'). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check62 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4 on the page.SummaryDifference0.1%

- Check84 days agoChange DetectedAdded a Locations section featuring North Holland (Amsterdam, Netherlands) and removed the old North Holland Locations entry; the HHS Vulnerability Disclosure link was removed. The footer now shows Revision: v3.3.3.SummaryDifference0.2%

Stay in the know with updates to 89Zr-Pembrolizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the 89Zr-Pembrolizumab in NSCLC Clinical Trial page.